#	Pagina
attuale pagina	/open-h2020/projects/212940/index.html
-1	/open-h2020/projects/200703/index.html

Opendata, web and dolomites

STriTuVaD SIGNED

In Silico Trial for Tuberculosis Vaccine Development

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

STriTuVaD project word cloud

Explore the words cloud of the STriTuVaD project. It provides you a very rough idea of what is the project "STriTuVaD" about.

endemic critical huge patients observations thousands globally strains india uses adaptive deadliest compliance extend strituvad almost efficacy innovation patient mdr generate made tuberculosis incidence accuracy antibiotic first found universal again countries augmented strain shorten recurrence fought silico tb probability trials simulator clinical host individual time tested physical infection infected predictive bacterial dangerous healthcare person drug drastically resistant diseases starting endpoints possibility once therapy hrt population recruited inactivation hrts reaction determinants statistically reduce world infectious trial predict always issue appearance virtual powered chances active coadjuvant therapies bayesian mostly combine immune public disease mobility

Project "STriTuVaD" data sheet

The following table provides information about the project.

Coordinator	ETNA BIOTECH SRL Organization address address: STRADA VINCENZO LANCIA 57 city: CATANIA postcode: 95100 website: www.etnabiotech.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Project website	http://www.strituvad.eu
Total cost	5˙050˙656 €
EC max contribution	4˙549˙527 € (90%)
Programme	1. H2020-EU.3.1.5. (Methods and data)
Code Call	H2020-SC1-2017-CNECT-2
Funding Scheme	RIA
Starting year	2018
Duration (year-month-day)	from 2018-02-01 to 2022-07-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ETNA BIOTECH SRL ETNA BIOTECH SRL Organization address address: STRADA VINCENZO LANCIA 57 city: CATANIA postcode: 95100 website: www.etnabiotech.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (CATANIA)	coordinator	1˙043˙750.00
2	INFECTIOUS DISEASE RESEARCH INSTITUTE INFECTIOUS DISEASE RESEARCH INSTITUTE Organization address address: EASTLAKE AVE E 1616 STE 400 city: SEATTLE WA postcode: 98102 website: www.idri.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (SEATTLE WA)	participant	1˙255˙027.00
3	UNIVERSITA DEGLI STUDI DI CATANIA UNIVERSITA DEGLI STUDI DI CATANIA Organization address address: PIAZZA UNIVERSITA 2 city: CATANIA postcode: 95131 website: www.unict.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (CATANIA)	participant	909˙393.00
4	THE UNIVERSITY OF SHEFFIELD THE UNIVERSITY OF SHEFFIELD Organization address address: FIRTH COURT WESTERN BANK city: SHEFFIELD postcode: S10 2TN website: www.shef.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (SHEFFIELD)	participant	465˙323.00
5	ARCHIVEL FARMA, SL ARCHIVEL FARMA, SL Organization address address: FOGARS DE TORDERA, 61 city: BADALONA postcode: 8916 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BADALONA)	participant	408˙360.00
6	ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA Organization address address: VIA ZAMBONI 33 city: BOLOGNA postcode: 40126 website: www.unibo.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (BOLOGNA)	participant	402˙047.00
7	STICHTING TUBERCULOSIS VACCINE INITIATIVE STICHTING TUBERCULOSIS VACCINE INITIATIVE Organization address address: Runderweg 6 city: LELYSTAD postcode: 8219 PH website: www.tbvi.eu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LELYSTAD)	participant	65˙625.00
8	THE ALL-INDIA INSTITUTE OF MEDICAL SCIENCES THE ALL-INDIA INSTITUTE OF MEDICAL SCIENCES Organization address address: ANSARI NAGAR city: NEW DELHI postcode: 110608 website: www.aiims.ac.in contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IN (NEW DELHI)	participant	0.00

Map

Project objective

Tuberculosis (TB) one of the world’s deadliest diseases: one third of the world’s population, mostly in developing countries, is infected with TB. But TB is becoming again very dangerous also for developed countries, due to the increased mobility of the world population, and the appearance of several new bacterial strains that are multi-drug resistant (MDR). There is now a growing awareness that TB can be effectively fought only working globally, starting from countries like India, where the infection is endemic. Once a person present the active disease, the most critical issue is the current duration of the therapy, because of the high costs it involved, the increased chances of non-compliance (which increase the probability of developing an MDR strain), and the time the patient is still infectious to others. One exciting possibility to shorten the duration of the therapy are new host-reaction therapies (HRT) as a coadjuvant of the antibiotic therapy. The endpoints in the clinical trials for HRTs are time to inactivation, and incidence of recurrence. While for the first it is in some cases possible to have a statistically powered evidence for efficacy in a phase II clinical trial, recurrence almost always require a phase III clinical trial with thousands of patients involved, and huge costs. In the STriTuVaD project we will extend our Universal Immune System Simulator to include all relevant determinants of such clinical trial, establish its predictive accuracy against the individual patients recruited in the trial, use it to generate virtual patients and predict their response to the HRT being tested, and combine them to the observations made on physical patients using a new in silico-augmented clinical trial approach that uses a Bayesian adaptive design. This approach, where found effective could drastically reduce the cost of innovation in this critical sector of public healthcare.

Deliverables

List of deliverables.
Report on the extensions implemented into the modeling simulation platform to reproduce the immune system â€“ TBC â€“ vaccines interactions and dynamics	Documents, reports	2020-04-16 10:07:03
Report on the creation of the subjects-specific and virtual patients libraries that will be used in the implementation of the in silico clinical trial	Documents, reports	2020-04-16 10:07:03
Governance and meetings: the governance bodies are set. SC meetings organised: logistic, preparation of programme, invitation of experts	Documents, reports	2020-04-16 10:07:03
Report on the data collection and selection on TB disease and candidate vaccines/treatments	Documents, reports	2020-04-16 10:07:03
First dissemination report	Documents, reports	2020-04-16 10:07:03
Public web site	Websites, patent fillings, videos etc.	2020-04-16 10:07:03
A coherent hierarchical Bayesian model encompassing the virtual and real data sources.	Documents, reports	2020-04-16 10:07:03
Report on the modeling simulation framework able to simulate human immune system dynamics	Documents, reports	2020-04-16 10:07:03
Dissemination plan	Documents, reports	2020-04-16 10:07:03

Take a look to the deliverables list in detail: detailed list of STriTuVaD deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STRITUVAD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STRITUVAD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.5.)

EUCANCan (2019)

EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine.

iReceptor Plus (2019)

ARCHITECTURE AND TOOLS FOR THE QUERY OF ANTIBODY AND T-CELL RECEPTOR SEQUENCING DATA REPOSITORIES FOR ENABLING IMPROVED PERSONALIZED MEDICINE AND IMMUNOTHERAPY